Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Intestinal Research
; : 355-378, 2020.
Article
in En
| WPRIM
| ID: wpr-834427
Responsible library:
WPRO
ABSTRACT
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
Full text:
1
Index:
WPRIM
Type of study:
Clinical_trials
/
Guideline
/
Observational_studies
Language:
En
Journal:
Intestinal Research
Year:
2020
Type:
Article